BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peterson RG, Jackson CV, Zimmerman KM, Alsina-Fernandez J, Michael MD, Emmerson PJ, Coskun T. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse. PLoS One. 2017;12:e0179856. [PMID: 28640857 DOI: 10.1371/journal.pone.0179856] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Martins FF, Marinho TS, Cardoso LEM, Barbosa-da-Silva S, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice. Cell Biochem Funct 2022. [PMID: 36169111 DOI: 10.1002/cbf.3751] [Reference Citation Analysis]
2 Lee H. Obesity-Associated Cancers: Evidence from Studies in Mouse Models. Cells 2022;11:1472. [PMID: 35563777 DOI: 10.3390/cells11091472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Reis-barbosa PH, Marcondes-de-castro IA, Marinho TDS, Aguila MB, Mandarim-de-lacerda CA. The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Marinho TS, Martins FF, Cardoso LEM, Aguila MB, Mandarim-de-Lacerda CA. Pancreatic islet cells disarray, apoptosis, and proliferation in obese mice. The role of Semaglutide treatment. Biochimie 2021:S0300-9084(21)00254-6. [PMID: 34742857 DOI: 10.1016/j.biochi.2021.10.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
5 Pontes-da-Silva RM, de Souza Marinho T, de Macedo Cardoso LE, Mandarim-de-Lacerda CA, Aguila MB. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist. Int J Obes (Lond) 2021. [PMID: 34465857 DOI: 10.1038/s41366-021-00955-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Soret PA, Magusto J, Housset C, Gautheron J. In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal. J Clin Med 2020;10:E36. [PMID: 33374435 DOI: 10.3390/jcm10010036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
7 Govindarajah V, Lee JM, Solomon M, Goddard B, Nayak R, Nattamai K, Geiger H, Salomonis N, Cancelas JA, Reynaud D. FOXO activity adaptation safeguards the hematopoietic stem cell compartment in hyperglycemia. Blood Adv 2020;4:5512-26. [PMID: 33166407 DOI: 10.1182/bloodadvances.2020001826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Zhang G, Wang X, Chung TY, Ye W, Hodge L, Zhang L, Chng K, Xiao YF, Wang YJ. Carbon tetrachloride (CCl4) accelerated development of non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF). BMC Gastroenterol 2020;20:339. [PMID: 33059584 DOI: 10.1186/s12876-020-01467-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
9 Hasan MN, Hwang YH, An JM, Shahriar SMS, Cho S, Lee YK. Oral GLP1 Gene Delivery by an Antibody-Guided Nanomaterial to Treat Type 2 Diabetes Mellitus. ACS Appl Mater Interfaces 2020;12:38925-35. [PMID: 32805914 DOI: 10.1021/acsami.0c09814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
10 Oligschlaeger Y, Shiri-Sverdlov R. NAFLD Preclinical Models: More than a Handful, Less of a Concern? Biomedicines 2020;8:E28. [PMID: 32046285 DOI: 10.3390/biomedicines8020028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
11 Neff EP. Farewell, FATZO: a NASH mouse update. Lab Anim (NY) 2019;48:151. [PMID: 31061508 DOI: 10.1038/s41684-019-0311-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sun G, Jackson CV, Zimmerman K, Zhang LK, Finnearty CM, Sandusky GE, Zhang G, Peterson RG, Wang YJ. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose. BMC Gastroenterol 2019;19:41. [PMID: 30885145 DOI: 10.1186/s12876-019-0958-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
13 Boland ML, Oldham S, Boland BB, Will S, Lapointe JM, Guionaud S, Rhodes CJ, Trevaskis JL. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction. World J Gastroenterol 2018; 24(16): 1748-1765 [PMID: 29713129 DOI: 10.3748/wjg.v24.i16.1748] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
14 Droz BA, Sneed BL, Jackson CV, Zimmerman KM, Michael MD, Emmerson PJ, Coskun T, Peterson RG. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco mouse. PLoS One. 2017;12:e0179808. [PMID: 28640904 DOI: 10.1371/journal.pone.0179808] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]